Exacompta Clairefontaine S.A. (ALEXA.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALEXA.PA in your mock portfolio yet.
The reported PE of 8.75 and EPS of €18.97 imply modest valuation and solid per‑share earnings, but without multi‑year revenue, margin, or cash‑flow data it is difficult to assert a clear positive or negative trend. The low PE could signal either undervaluation or a market discount for structural challenges in a mature, paper‑based business. Overall, the financial picture looks stable rather than clearly improving or deteriorating based on the limited metrics provided.
The stock trades at €166.00, slightly above its 200‑day moving average of €165.63, and has risen 1.8% over the last month, indicating a mild positive bias but no strong momentum. Trading essentially in line with the 200‑day average suggests the market views the name as fairly valued near current levels. Without RSI data or a stronger price trend, the technical picture is balanced rather than clearly bullish or bearish.
Alternative data show very limited digital reach and essentially flat or slightly declining social metrics, which is a weak signal for brand momentum in a consumer‑facing, stationery‑oriented business. Web traffic of roughly 2,091 visitors per month is extremely low for a listed company, and social channels show stagnation rather than engagement growth. These indicators point to limited online growth dynamics, a mild negative for long‑term demand and brand relevance.
Overall, Exacompta Clairefontaine S.A. appears neutral from a stock‑performance standpoint: the valuation is modest and the price sits just above its 200‑day moving average, but there is no strong evidence of accelerating growth or momentum. Alternative data suggest a weak digital footprint and stagnant brand engagement, which tempers any value argument implied by the low PE. Absent clearer signs of improving fundamentals or digital traction, the risk‑reward profile looks balanced rather than distinctly attractive or concerning.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started